FDA Approves Moderna’s First mRNA Flu Vaccine for Older Adults
Cambridge, Saturday, 8 August 2026.
On August 5, 2026, the FDA approved Moderna’s mFlusiva, cutting vaccine production lead times from six months to just two, opening a major new commercial frontier for mRNA technology.
FDA Grants Historic Approval for mRNA Influenza Vaccine
On August 5, 2026, the U.S. Food and Drug Administration approved Moderna’s mFlusiva, marking the first licensure of an mRNA-based influenza vaccine for adults aged 50 and older [2][3][4]. This regulatory milestone follows a Phase 3 trial involving 40,805 participants across 11 countries, which demonstrated the vaccine’s safety and efficacy profile [2][4]. The approval distinguishes between age groups, granting standard approval for adults aged 50 to 64 and accelerated approval for those 65 and older, contingent upon a post-marketing confirmatory study [3][4]. Moderna, traded on NASDAQ as MRNA, positions this product as a critical expansion of its mRNA platform beyond COVID-19 interventions [4].
Manufacturing Efficiency and Technological Advantages
The mFlusiva vaccine leverages mRNA technology to significantly compress production timelines compared to traditional egg-based methods. While conventional vaccine development typically requires approximately six months of lead time, the mRNA platform reduces this window to between two and three months [2]. This reduction represents a potential decrease in production time of 50 percent when comparing the traditional timeline to the upper bound of the new mRNA window [2]. Such agility allows public health officials to respond more dynamically to emerging viral strains each season, addressing a key limitation of legacy manufacturing processes [1][3]. During Phase 3 trials, the vaccine showed a relative efficacy of 26.6 percent against protocol-defined influenza-like illness, with an incidence rate of 2 percent in the mRNA group versus 2.8 percent in the standard-comparator group [2].
Market Availability and Regulatory Context
Despite the approval, distribution plans vary among major pharmacy chains, with some citing ample existing supply of traditional vaccines for the 2026-27 flu season [1]. While Wilson’s Pharmacy in Pittsburgh confirmed plans to stock mFlusiva by September 2026, giants like CVS and Giant Eagle indicated they would evaluate demand before adding the shot to their offerings [1]. The approval process faced earlier regulatory hurdles, including an initial refusal-to-file notice in February 2026, which was reversed following public disclosure and pressure [3][4]. This decision occurs amidst a complex political landscape, where Health and Human Services Secretary Robert F. Kennedy Jr. has expressed skepticism regarding mRNA technology for respiratory viruses, though the FDA advisory committee unanimously concluded benefits outweigh risks [1][2].